1. Home
  2. DERM vs DTIL Comparison

DERM vs DTIL Comparison

Compare DERM & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Journey Medical Corporation

DERM

Journey Medical Corporation

BUY

Current Price

$6.19

Market Cap

190.3M

Sector

Health Care

ML Signal

BUY

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

BUY

Current Price

$6.20

Market Cap

197.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DERM
DTIL
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
197.9M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
DERM
DTIL
Price
$6.19
$6.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$13.75
★ $29.40
AVG Volume (30 Days)
175.0K
★ 237.8K
Earning Date
11-11-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 34.72
N/A
EPS
★ N/A
N/A
Revenue
$61,858,000.00
★ $1,070,000,000.00
Revenue This Year
$31.55
N/A
Revenue Next Year
$60.28
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 10.20
N/A
52 Week Low
$4.31
$3.53
52 Week High
$9.56
$9.62

Technical Indicators

Market Signals
Indicator
DERM
DTIL
Relative Strength Index (RSI) 37.92 35.23
Support Level $5.95 $6.02
Resistance Level $6.59 $7.65
Average True Range (ATR) 0.41 0.39
MACD -0.07 -0.01
Stochastic Oscillator 9.18 15.89

Price Performance

Historical Comparison
DERM
DTIL

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Share on Social Networks: